Skip to content
DraconiticResearch
Search Sources API
189,280 studies31 sourcesUpdated 48 min ago
Peer-reviewedCC BY 4.0Frontiers in Oncology

Novel aptamer-based strategies for addressing aggressive and heterogeneous triple-negative breast cancer

  • Natassia Silva de Araujo1
  • Aline dos Santos Moreira1
  • Rayane da Silva Abreu1
  • Julia Badaró Mendonça1
  • Tayanne Felippe Sassaro1
  • Wim Degrave1
  • Tatiana Martins Tilli2,3
  • Mariana Caldas Waghabi1
  1. 1Laboratory of Applied Genomics and Bioinnovations, Oswaldo Cruz Institute, Fiocruz
  2. 2Laboratory of Clinical and Experimental Pathophysiology, Oswaldo Cruz Institute, Fiocruz
  3. 3Translational Oncology Platform, Center for Technological Development in Health, Fiocruz
Open at sourcePDFDOICite

Abstract

Introduction: Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous subtype of breast cancer associated with poor prognosis, limited therapeutic options, and high recurrence rates.

Methods: In this study, we evaluated the therapeutic potential of an AptaBreast panel (AB-panel) previously identified for its ability to recognize TNBC cells specifically. Functional assays were performed in various TNBC cell lines representing distinct intrinsic subtypes, as well as in non-tumoral cells (MCF10A).

Results: Functional assays revealed that the aptamers effectively reduced tumor cell viability, proliferation, migration and colony formation in various TNBC cell lines. Importantly, the combined treatment with all five aptamers resulted in an enhanced overall antitumor effect. Notably, the aptamers demonstrated selective action on tumor cells without significant cytotoxicity to non-tumoral cells (MCF10A).

Discussion: The observed effects support the potential of these aptamers as therapeutic candidates for TNBC and warrant further investigation into their molecular targets and mechanisms of action. Collectively, our findings highlight their potential across different TNBC cellular models, while further studies are needed to assess their therapeutic efficacy, safety, and applicability in more complex models. These results provide a basis for future preclinical studies aimed at further evaluating their potential in TNBC.

Related

  1. Looking Beyond KD for Aptamer Validation: Disentangling Specific Aptamer Binding from Electrostatic Association for Basic Protein Targets
    Connor D. Flynn, Shana O. Kelley, Dingran Chang
    ChemRxivPreprintCC BYFull textMolecular biology & gene regulationChemRxiv
  2. High-Affinity Anti-nivolumab DNA Aptamer: A Novel Capture Reagent for Its Bioanalysis by an Enzyme-Linked Aptamer Assay
    Taisei Hojo, Nao Kobayashi, Chiho Hirayama +8
    Chemical and Pharmaceutical BulletinPeer-reviewedCC BY-NCFull textMolecular biology & gene regulationJ-STAGE
  3. Preparation of electrochemical aptamer-based sensors: a direct aryl diazonium grafting approach
    Essam Dief, Wenxian Tang, Liam Carroll +2
    Chemical CommunicationsPeer-reviewedCC BY-NCFull text8 citedMolecular biology & gene regulationHAL
  4. Combining AlphaFold 3 with microscale thermophoresis for aptamer optimisation
    A. Harkai, T. Meszaros
    bioRxivPreprintCC BYFull textMolecular biology & gene regulationbioRxiv
  5. Unconventional DNA architecture in a dopamine–bound aptamer complex
    Emily Hoi Pui Chao, Eric Largy, Yunus A. Kaiyum +5
    Nature CommunicationsPeer-reviewedCC BY 4.0Full text8 citedStructural biologyGeneral biologyCrossrefHALOpenAlex

Cite

BibTeXRIS
BibTeX
@article{araujo2026novel,
  title = {{Novel aptamer-based strategies for addressing aggressive and heterogeneous triple-negative breast cancer}},
  author = {Natassia Silva de Araujo and Aline dos Santos Moreira and Rayane da Silva Abreu and Julia Badaró Mendonça and Tayanne Felippe Sassaro and Wim Degrave and Tatiana Martins Tilli and Mariana Caldas Waghabi},
  journal = {Frontiers in Oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1943528},
  url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1943528/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Novel aptamer-based strategies for addressing aggressive and heterogeneous triple-negative breast cancer
AU  - Natassia Silva de Araujo
AU  - Aline dos Santos Moreira
AU  - Rayane da Silva Abreu
AU  - Julia Badaró Mendonça
AU  - Tayanne Felippe Sassaro
AU  - Wim Degrave
AU  - Tatiana Martins Tilli
AU  - Mariana Caldas Waghabi
PY  - 2026
DA  - 2026/10/21
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1943528
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2026.1943528/full
AB  - Introduction: Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous subtype of breast cancer associated with poor prognosis, limited therapeutic options, and high recurrence rates.  Methods: In this study, we evaluated the therapeutic potential of an AptaBreast panel (AB-panel) previously identified for its ability to recognize TNBC cells specifically. Functional assays were performed in various TNBC cell lines representing distinct intrinsic subtypes, as well as in non-tumoral cells (MCF10A).  Results: Functional assays revealed that the aptamers effectively reduced tumor cell viability, proliferation, migration and colony formation in various TNBC cell lines. Importantly, the combined treatment with all five aptamers resulted in an enhanced overall antitumor effect. Notably, the aptamers demonstrated selective action on tumor cells without significant cytotoxicity to non-tumoral cells (MCF10A).  Discussion: The observed effects support the potential of these aptamers as therapeutic candidates for TNBC and warrant further investigation into their molecular targets and mechanisms of action. Collectively, our findings highlight their potential across different TNBC cellular models, while further studies are needed to assess their therapeutic efficacy, safety, and applicability in more complex models. These results provide a basis for future preclinical studies aimed at further evaluating their potential in TNBC.
SN  - 2234-943X
ER  -